ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Alkermes plc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$42.97+1.75 (+4.25%)
Close on Oct 19, 2026
- Market cap
- $7.45B
- P/E (TTM)
- 113.1
- Dividend yield
- –
Share price
+$12.71 (+42.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Alkermes plc. grew revenue 10.8% to $1.67B over the twelve months to Jun 30, 2026. Operating income fell 68.7% to $117.26M, moving the operating margin from 24.9% to 7.0%. Free cash flow was $221.65M, down 53.8% from a year earlier.
Revenue
$1.67B
+10.8% vs. a year earlier
Operating income
$117.26M
-68.7% vs. a year earlier
Free cash flow
$221.65M
-53.8% vs. a year earlier
EPS, diluted
$0.38
-81.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $7.45B
- P/E ratio
- 113.1
- Price to sales
- 4.47
- Price to book
- 4.12
- Dividend yield
- –
- Free cash flow yield
- 2.97%
Fundamentals
- Revenue
- $1.67B
- Net income
- $66.12M
- EPS, diluted
- $0.38
- Free cash flow
- $221.65M
- Book value per share
- $10.43
- Diluted shares
- 173M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
$1.67B+10.8% YoY
Gross profit
$1.41B+10.0% YoY
Operating income
$117.26M-68.7% YoY
Net income
$66.12M-81.0% YoY
EPS, diluted
$0.38-81.7% YoY
Free cash flow
$221.65M-53.8% YoY
Reported periodTrailing twelve months